Chemotherapy and novel therapeutics before radical prostatectomy for high-risk clinically localized prostate cancer Journal Article


Authors: Cha, E. K.; Eastham, J. A.
Article Title: Chemotherapy and novel therapeutics before radical prostatectomy for high-risk clinically localized prostate cancer
Abstract: Although both surgery and radiation are potential curative options for men with clinically localized prostate cancer, a significant proportion of men with high-risk and locally advanced disease will demonstrate biochemical and potentially clinical progression of their disease. Neoadjuvant systemic therapy before radical prostatectomy (RP) is a logical strategy to improve treatment outcomes for men with clinically localized high-risk prostate cancer. Furthermore, delivery of chemotherapy and other systemic agents before RP affords an opportunity to explore the efficacy of these agents with pathologic end points.Neoadjuvant chemotherapy, primarily with docetaxel (with or without androgen deprivation therapy), has demonstrated feasibility and safety in men undergoing RP, but no study to date has established the efficacy of neoadjuvant chemotherapy or neoadjuvant chemohormonal therapies. Other novel agents, such as those targeting the vascular endothelial growth factor receptor, epidermal growth factor receptor, platelet-derived growth factor receptor, clusterin, and immunomodulatory therapeutics, are currently under investigation. © 2015 Elsevier Inc.
Keywords: neoadjuvant therapy; chemotherapy; novel therapeutics; high-risk prostate cancer
Journal Title: Urologic Oncology: Seminars and Original Investigations
Volume: 33
Issue: 5
ISSN: 1078-1439
Publisher: Elsevier Inc.  
Date Published: 2015-05-01
Start Page: 217
End Page: 225
Language: English
DOI: 10.1016/j.urolonc.2014.11.020
PROVIDER: scopus
PUBMED: 25596644
DOI/URL:
Notes: Export Date: 3 June 2015 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. James Eastham
    537 Eastham
  2. Eugene K. Cha
    99 Cha